At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 12 enrolled
Drug / intervention
Ceftazidime/avibactamdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Steady-state Pharmacokinetics of Ceftazidime/Avibactam in CF
In Brief
A Phase 4 clinical trial evaluating Ceftazidime/avibactam for Cystic Fibrosis. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The purpose of this research study is to characterize the pharmacokinetics of intravenous ceftazidime/avibactam in patients with Cystic Fibrosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 2015
Enrollment StartSep 2015
Primary CompletionOct 2016
TodayJul 2026
First PostedJul 22, 2015
Enrollment StartSep 1, 2015
Primary CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 10.9 years ago
Interventions
Ceftazidime/avibactamdrug
Ceftazidime/avibactam 2.5gm iv q8h for 3 doses